PharVision Advisers’s CryoPort CYRX Stock Holding History

PharVision Advisers’s Portfolio CYRX Stock Details CYRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,014	Closed	-$91.2K	–	79
2026 Q1	$91.2K	Sell	11,014 -348	-3%	-$3.14K	0.93%	56
2025 Q4	$109K	Sell	11,362 -5,136	-31%	-$48.5K	0.06%	648
2025 Q3	$156K	Buy	16,498 +5,531	+50%	+$46.6K	0.09%	563
2025 Q2	$81.8K	Buy	+10,967	New	+$68.1K	0.12%	260
2025 Q1	–	Sell	-33,326	Closed	-$259K	–	326
2024 Q4	$259K	Buy	+33,326	New	+$248K	0.22%	202

Other funds holding CYRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

PharVision Advisers's CYRX Position: Q2 2026 in Review

PharVision Advisers sold out of CryoPort (CYRX) in Q2 2026, closing a stake of 11,014 shares — an estimated $91.2K sold.

PharVision Advisers first reported a position in CYRX in Q4 2024 and held it in 5 quarters. The position peaked at $259K in Q4 2024. 184 funds tracked by Wall St. Rank hold CYRX as of Q2 2026.

PharVision Advisers reported no remaining CryoPort position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 11,014 CryoPort shares in Q2 2026, an estimated $91.2K.
PharVision Advisers first reported a position in CryoPort in Q4 2024 and held it in 5 quarters.
PharVision Advisers's CryoPort position peaked at $259K in Q4 2024.
184 funds tracked by Wall St. Rank held CryoPort as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.